Overview

EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2025-11-27

Target enrollment:

Participant gender:

Summary

The PANOVA-4 study is designed to evaluate the safety and efficacy of Tumor Treating Fields (TTFields) therapy together with atezolizumab, gemcitabine and nab-paclitaxel, for the treatment of metastatic pancreatic cancer. The study is intended for patients who have been diagnosed with metastatic pancreatic cancer and have not received prior systemic therapy.

Phase:

PHASE2

Details

Lead Sponsor:

NovoCure Ltd.

Treatments:

130-nm albumin-bound paclitaxel
Albumin-Bound Paclitaxel
atezolizumab
Gemcitabine